Aardvark Therapeutics, Inc. (AARD)

In the past six months, Aardvark Therapeutics' stock experienced positive analyst coverage from Oppenheimer, William Blair, and Raymond James. The company announced FDA alignment on a protocol amendment to expand the Phase 3 HERO trial population and the dosing of the first patient in Australia for the Phase 3 HERO trial. The company reported its quarterly earnings data on November 13, 2025, posting ($0.75) earnings per share, topping analysts' consensus estimates. The CEO and CFO have continued to buy shares. AARD stock has increased by 13.0% since the beginning of the year and 24.82% over the past six months.

There is no specific information available regarding demand seasonality for Aardvark Therapeutics, Inc.'s products or services. As a clinical-stage biopharmaceutical company, its revenue generation is primarily tied to the successful development and commercialization of its drug candidates, rather than seasonal consumer demand.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics that activate innate homeostatic pathways for metabolic diseases, particularly those related to hunger. The company operates in the Healthcare sector, specifically within the Biotechnology and Pharmaceutical Products industries. Its primary product candidates include ARD-101, an oral agonist in Phase 3 trials for hyperphagia associated with Prader-Willi Syndrome (PWS) and in Phase 2 for hypothalamic obesity, and ARD-201, a fixed-dose combination in Phase 1 trials for obesity, with planned Phase 2 trials focusing on weight rebound prevention and durable weight loss.

Aardvark Therapeutics, Inc. is headquartered in San Diego, California, and has research facilities in Cambridge, Massachusetts. Clinical trials for ARD-101 are being conducted in Australia, Canada, and the United Kingdom.

Aardvark Therapeutics' brand reputation is largely positive, driven by promising clinical developments and strong analyst sentiment, with a consensus rating of "Moderate Buy". Positive news regarding clinical trial progress contributes to a favorable reputation. However, some analyses have raised concerns about the scientific basis of ARD-101's mechanism, potentially challenging its scientific reputation, though overall market and analyst sentiment remains largely positive.

Aardvark Therapeutics, Inc. has a diverse ownership structure, with individual investors holding the largest stake at around 32%. Institutional investors and hedge funds also hold a significant portion of shares. Major institutional owners include Decheng Capital LLC, Citadel Advisors Llc, Laurion Capital Management LP, Vanguard Group Inc, Adage Capital Partners Gp, L.l.c., Millennium Management Llc, BlackRock, Inc., Silverarc Capital Management, Llc and Schonfeld Strategic Advisors LLC. Private equity firms hold approximately 28% of the shares, while hedge funds control about 6.2%.